Cardiovascular Renal Metabolic

ESC Congress 2025 Releases its Late-Breaking Scientific Programme

ESC Congress 2025 Scientific Programme

ADA 25: Final Results of the CATALYST Trial

Watch time: 13m 50s
ADA 25: Clinical Implications of STRIDE for Endocrinologists

Watch time: 9m 52s
ADA 25: MariTide Treatment for Obesity in Patients with or without T2D

Harold Bays

Watch time: 6m 23s

Sue Pedersen

Watch time: 42m 3s (5 videos)
ADA 25: PATHWEIGH: Weight Management in Primary Care

Leigh Perreault

Watch time: 4m 46s
ERA 25: Albuminuria, eGFR Dip and Disease Severity & Empagliflozin

William Herrington

Watch time: 3m 10s
ERA 25: Treating Obesity in 2025 and Beyond

Ruben Nogueiras

Watch time: 4m 16s
ERA 25: Switching from sMRAs to Finerenone

Beatriz Fernandez Fernandez

Watch time: 10m 48s
ERA 25: eGFR Dips and Disease Severity on Empagliflozin

Watch time: 2m 52s
Real-World Data for CV and Renal Outcomes in DKD

David Wheeler

Watch time: 2m 39s

Paola Fioretto, Rajiv Agarwal

Watch time: 28m 13s (3 videos)

David Wheeler, Carol Pollock,

Muthiah Vaduganathan

Sydney Tang , ,

Stefan Anker, Shelley Zieroth, Andrew JS Coats, et al

Watch time: 5h 14m 55s (31 videos)

Lee Kaplan, Fatima Cody Stanford, Filip Knop, et al

Andrew JS Coats, Stefan Anker

Neha Pagidipati, Linda Mellbin, , et al

Watch time: 2h (19 videos)

James Burton, Shelley Zieroth, Clara Bonanad Lozano , et al

Watch time: 1h 34m (7 videos)

Fausto J Pinto, John Spertus, , et al

Debbie L Cohen, Raymond R Townsend

Raymond B Fohtung, Michael W Rich

Read time: 13m 29s

Paul Kalra

Watch time: 12m 41s (2 videos)

Media

AHA 23: Preventive Cardiology in 2023

Michael Honigberg

Watch time: 7m 3s
AHA 23: 3 Trials That Will Change My Practice

Dipti Itchhaporia

Watch time: 7m 20s
AHA 23 Late-Breaker Discussion: The SELECT Trial

A Michael Lincoff , Harriette Van Spall

Watch time: 21m 35s
CardioNerds @AHA23: Presidential Advisory on CKM Health

Ramy Doss, Chiadi Ndumele

Watch time: 14m 32s
ESC 23 Late-Breaker Discussion: The STEP HFpEF Trial

Harriette Van Spall, Mikhail Kosiborod

Watch time: 13m 24s
ESC 23: Day 1 Wrap-Up with Dr Alasnag and Dr Al-Shaibi

Mirvat Alasnag, Khaled Al-Shaibi

Watch time: 13m 28s
ECO 23: Impact of Obesity on Heart Failure Outcomes

Laura Meems

Watch time: 7m 7s

James Burton, Shelley Zieroth, Clara Bonanad Lozano , et al

Watch time: 1h 34m (7 videos)

Fausto J Pinto, John Spertus, , et al

Obesity Management Strategies in 2023

Harold Bays

Watch time: 17m 7s
ACC 23 Late-breaking Discussion: The COORDINATE-Diabetes Trial

Harriette Van Spall, Neha Pagidipati, Christopher B Granger, et al

Watch time: 17m 32s
EP 87: Gut Microbiome and Heart Health: The 3 Compounds You Need to Know About with Dr Vuyisich

Ankur Kalra, Momchilo Vuyisich,

Listen time: 45m 50s

Media

ADA 25: PATHWEIGH: Weight Management in Primary Care

Leigh Perreault

Watch time: 4m 46s
ADA 25: MariTide Treatment for Obesity in Patients with or without T2D

Harold Bays

Watch time: 6m 23s
ADA 25: Clinical Implications of STRIDE for Endocrinologists

Watch time: 9m 52s

Sue Pedersen

Watch time: 42m 3s (5 videos)
ADA 25: Final Results of the CATALYST Trial

Watch time: 13m 50s
ERA 25: Treating Obesity in 2025 and Beyond

Ruben Nogueiras

Watch time: 4m 16s
Real-World Data for CV and Renal Outcomes in DKD

David Wheeler

Watch time: 2m 39s
ERA 25: eGFR Dips and Disease Severity on Empagliflozin

Watch time: 2m 52s
ERA 25: Albuminuria, eGFR Dip and Disease Severity & Empagliflozin

William Herrington

Watch time: 3m 10s
ERA 25: Switching from sMRAs to Finerenone

Beatriz Fernandez Fernandez

Watch time: 10m 48s
SUGAR: Amphilimus-eluting Stents VS Zotarolimus-eluting Stents in Patients With DB

Rafael Romaguera

Watch time: 8m 19s
ESC HF 25: The PRAISE-HFrEF Study

Varun Sundaram

Watch time: 4m 10s

Articles

SGLTi and GLP-1 in HF

Jose Lopez

,

Tracy Makuvire

,

Jonathan D Davis

,

Salvatore Carbone

,

Published:

13 May 2025

Citation:

US Cardiology Review 2025;19:e12.

DOI:

https://doi.org/10.15420/usc.2024.44
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 1744
  • Downloads: Downloads 165
  • Read time: 26m 29s

HDL Cholesterol and Adverse Outcomes

Marc P Allard-Ratick

,

Pratik Sandesara

,

Arshed A Quyyumi

,

Laurence S Sperling

,

Published:

12 March 2019

Citation:

US Cardiology Review 2019;13(1):49–53

DOI:

https://doi.org/10.15420/usc.2019.3.2
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 5556
  • Downloads: Downloads 44
  • Citations: 9

Diabetic Cardiomyopathy: Five Major Questions with Simple Answers

Miguel Alejandro Rodriguez-Ramos

,

Published:

12 March 2019

Citation:

US Cardiology Review 2019;13(1):46–8

DOI:

https://doi.org/10.15420/usc.2018.18.2
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 1984
  • Downloads: Downloads 28

Diabetes Drugs and Cardiovascular Event Reduction: A Paradigm Shift

Erik M Kelly

,

Donald E Cutlip

,

Citation:

US Cardiology Review 2018;12(1):46–50.

DOI:

https://doi.org/10.15420/usc.2017:35:1
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 2052
  • Downloads: Downloads 10